ALTB-268
Ulcerative Colitis
About AltruBio
AltruBio is a private, clinical-stage biotech focused on novel biologics that modulate T-cell activity via the PSGL-1 checkpoint. The company's pipeline is anchored by ALTB-268, a next-generation candidate for ulcerative colitis now in Phase 2a, with plans for indication expansion. Having recently secured a significant $225M Series B financing, AltruBio has strengthened its financial position to advance its clinical programs. The company operates with a dual headquarters in San Francisco and a key R&D center in Taipei, Taiwan.
View full company profileAbout AltruBio
AltruBio is a private, clinical-stage biotech focused on novel biologics that modulate T-cell activity via the PSGL-1 checkpoint. The company's pipeline is anchored by ALTB-268, a next-generation candidate for ulcerative colitis now in Phase 2a, with plans for indication expansion. Having recently secured a significant $225M Series B financing, AltruBio has strengthened its financial position to advance its clinical programs. The company operates with a dual headquarters in San Francisco and a key R&D center in Taipei, Taiwan.
View full company profileTherapeutic Areas
Other Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| BB265 | BiomeBank | Phase 1 |
| PALI-2108 | Palisade Bio | Phase 2 |
| AIM-HI-UC | PathAI | Clinical Trials |
| Patient Stratification in Ulcerative Colitis | Enable Medicine | Research |
| Mesalazine (Lifecycle Management) | Dr. Falk Pharma | Approved/Phase 3 |
| AhR Agonist Program | Azora Therapeutics | Phase 1b |
| R-3750 | Virtici | Phase 1 |
| GPR35 Inhibitor | ThirtyFiveBio | Preclinical |
| BT-600 | Biora Therapeutics | Phase 1 |
| Asacol® (mesalazine) | Tillotts Pharma | Approved |
| MB310 | Microbiotica | Phase 1b |
| '1805 | Revolo Biotherapeutics | Phase 2 (Planned) |